Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Sirolimus Use During Pregnancy in Women with Lymphangioleiomyomatosis
Krishna, R. Vijay , Johnson, Simon R. , Ataya, Ali , Baqir, Misbah , Baldi, Bruno Guedes , Girod, C, Gupta, Nishant , Gupta, Nishant , Krishna, Rachana, Diesler, Rémi , Henske, Elizabeth P. , Xu, Kai‐Feng

Mayo Clinic

Annals of the American Thoracic Society | June 30, 2025 | Volume: 22 | Issue: 11 | Pages: 1794-1797

10.1513/annalsats.202504-433rl | PMID 40587229 Get It

An Observational Analysis of a Large Cohort of Pneumocystis jirovecii Pneumonia
Pulsipher, Aaron M. , Vikram, Holenarasipur R. , Gotway, Michael B. , Cartin‐Ceba, Rodrigo , Henry, Kyle J, Johnson, Alec M, Gassner, Ryan R , Zhou, Kevin , Green, D., Thompson, Emily , Sen, Ayan , Lee, Augustine S. , Ham, Kealy R., Green, Danielle , Thompson, Emily R , Sen, Ayan , Lee, Augustine S , Ham, Kealy , Vikram, Holenarasipur R. , Gotway, Michael B , Pulsipher, Aaron M , Henry, Kyle J, Johnson, Alec M, Limper, Andrew H.

Mayo Clinic

Open Forum Infectious Diseases | June 28, 2025 | Volume: 12 | Issue: 7 | Pages: No page available

10.1093/ofid/ofaf390 | PMID 40708624 Get It

Abstract Background Pneumocystis jirovecii pneumonia (PCP) is increasingly seen in patients who are non-HIV immunocompromised hosts, yet modern risk factors and outcomes are poorly recognized and defined. Methods A retrospective review was conducted of adult patients who met criteria for proven or probable PCP from 2017 to 2024 across a large academic multicenter health system. The primary outcome was mortality among cohorts, defined by etiology of immunosuppression through univariate and age-adjusted logistic regression. Secondary analyses included trends in annual diagnoses and testing patterns. Results A total of 701 patients met criteria for inclusion, representing one of the largest clinically characterized cohorts of PCP to date. The median age was 65 years (IQR, 54–73) and 62% were male. The most common risk groups were hematologic malignancy (32.2%), solid tumor cancers receiving chemotherapy (22.4%), and autoimmune disease with immunosuppression (17.7%). Annual PCP diagnoses increased at a rate of 15.8% (95% CI, 8.9%–23.2%) in parallel with increased testing. Only 5.4% of patients were receiving prophylaxis at the time of diagnosis. Overall mortality was 20% (95% CI, 17%–23%) and highest in cirrhosis (adjusted odds ratio, 6.24; 95% CI, 2.84–13.69; P < .001). Conclusions PCP in the current era affects a broad range of patients who are immunocompromised, with high associated mortality and low rates of prophylaxis. Patients with solid tumors and those with cirrhosis are at particularly high risk of mortality. These findings highlight the need to reassess and redefine PCP prophylaxis guidelines in specific populations and our understanding of who is at risk.
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma
Breen, William G. , Anderson, S. Keith , Brown, Paul D. , Yan, Elizabeth , Kizilbash, Sani H. , Anderson, Daniel M. , Tran, David , Mazurczak, Miroslaw, Geoffroy, Francois J., Leinweber, Clinton, Dixon, Jesse G. , Anderson, S Keith , Yan, Elizabeth S, Kizilbash, Sani, Galanis, Eva, Kizilbash, Sani H , Sarkaria, Jann N. , Galanis, Evanthia , Tran, David D. , Johnson, Derek R. , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology | June 27, 2025 | Volume: 27 | Issue: 10 | Pages: 2661-2670

10.1093/neuonc/noaf156 | PMID 40579995 Get It

Abstract Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus placebo with standard concurrent and adjuvant TMZ. Radiation dose was 60 Gy in 30 fractions. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life. Results Thirteen patients were enrolled in the phase I component and established the MTD and phase II dose of 150 mg given daily. A total of 204 patients were enrolled in the phase II component. OS was not different between arms (median OS 15.6 months for dasatinib compared to 19.3 months for placebo, hazard ratio:1.21 favoring placebo, 95% CI: 0.88–1.65, log-rank P-value: .238). Similarly, PFS was not significantly different between the dasatinib and placebo arms. There was a significant increase in anemia, nausea, and creatinine elevation with dasatinib, but significantly more grade 3 lymphopenia with placebo. Conclusions The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma. Clinical Trial Identifier NCT00869401.
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
Boyiadzis, Michael , Wei, Andrew H. , Freeman, Sylvie , Chyla, Brenda , Hersey, Sarah, Patel, Reshma, Maloney, Brian, Zumofen, Marie-Hélène Blanchet , Hoef, Marlies Van, Wulff, Beate, Obourn, Vanessa, Patel, Shalaka, Menezes, Daniel L. , Bengoudifa, Bourras‐Rezki, Dimier, Natalie , Wei, Andrew H , Paiva, Bruno , Kaspers, Gertjan J.L. , Shi, Qian , Prior, Thomas J. , Roboz, Gail J. , Prébet, Thomas

Mayo Clinic

Cancer | June 27, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35960 | PMID 40576165 Get It

AbstractDespite advances in acute myeloid leukemia (AML) treatment, significant unmet medical needs remain. Surrogate end points for overall survival can accelerate the approval of novel therapies. Measurable residual disease (MRD) is a promising surrogate end point candidate, providing a sensitive and quantitative assessment of disease burden. Numerous studies have demonstrated that negative MRD status—across diverse methodologies, assessment timepoints and thresholds, patient subgroups, and clinical settings—independently predicts improved survival. Although MRD can inform therapeutic decisions at the patient level, its formal integration as a primary surrogate end point in regulatory frameworks for clinical trials requires rigorous validation. MRD Partnership and Alliance in AML Clinical Treatment (MPAACT) is a research consortium among industry and academic leaders. MPAACT actively engages with regulatory agencies, health technology assessment bodies, technology vendors, and patient groups to establish a pathway for validating MRD as a surrogate end point in AML clinical trials. For the current article, the authors reviewed the status of MRD assessment, its use in recent clinical trials, current MRD assessment methodologies, standardization, regulatory guidance, statistical approaches, and patient access considerations necessary for MRD to become a surrogate clinical trial end point. The extensive collaboration between MPAACT, global industry, and academic partners—including data sharing and resource integration—underscores the collective commitment to advancing AML therapies. Establishing MRD as a surrogate end point could accelerate the development and approval of innovative treatments, ultimately improving patient outcomes.
Factors Associated With Quality of Life 10 Years Following Esophagectomy With Gastric Advancement
Treffalls, John A. , Buch, Chirag A., Das, Nitin A. , Medina, Rebecca A., Koch, Marc, DeArmond, Daniel T. , Johnson, Scott, Jacobsen, Christian, Koch, Marc

Mayo Clinic

Foregut: The Journal of the American Foregut Society | June 26, 2025 | Volume: 5 | Issue: 3 | Pages: 221-228

10.1177/26345161251346926 Get It

Objective: This study evaluated the surgical and long-term patient-reported quality of life outcomes of patients undergoing esophagectomy with gastric advancement. Methods: A retrospective review was performed of all patients undergoing esophagectomy with gastric advancement from 2005 to 2016. Quality of life outcomes were evaluated using the European Organization for research and treatment of cancer quality of life questionnaire - esophageal cancer module (QLQ-OES18), which covered 10 symptom scales: dysphagia, trouble swallowing saliva, choking when swallowing, eating, dry mouth, trouble with taste, trouble with coughing, trouble speaking, reflux, and pain. Results: A total of 129 patients were followed up to 16 years (791.3 patient-years). The median age was 63.5 (IQR 55.9-69.3) years, and 79.9% were male. Eighty-six percentage (111/129) of patients had esophageal malignancy as their operative indication. Median survival was 7.1 years, with patients with benign disease experiencing longer postoperative survival ( P = .006). The response rate to QLQ-OES18 surveys was 53.7% (22/41; median follow-up: 10.4 years). Patients who experienced early postoperative complications were more likely to report trouble with coughing ( P = .032) than those who did not experience early complications. However, postoperative leaks were not associated with worsened QOL. Of note, age ≥ 65 years, obesity status, surgical indication, location of the primary esophageal lesion, tumor stage, and the occurrence of delayed postoperative complications were not associated with long-term QOL (all P > .05). Conclusion: Patients undergoing esophagectomy with gastric advancement generally had good quality of life 10 years postoperatively, though early postoperative complications and gender appeared to influence symptom burden. These findings may improve pre and postoperative patient counseling.
Dissection of Neurotropic Theiler's Murine Encephalomyelitis Virus Induced Brain Atrophy in Single MHC Class I Mice of C57BL /6 Background
Wininger, Katheryn M. , Anani‐Wolf, Delaney, Hinson, Destin T , Hansen, Michael, Johnson, Aaron J. , Anani-Wolf, Delaney, Ayasoufi, Katayoun , Jin, Fang , Johnson, Aaron J.

Mayo Clinic

The FASEB Journal | June 26, 2025 | Volume: 39 | Issue: 12 | Pages: No page available

10.1096/fj.202501045r | PMID 40536098 Get It

ABSTRACT Brain atrophy is a common feature of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and more recently SARS‐CoV‐2 infection for which the neuroinflammatory mechanism is not fully understood. Nevertheless, neuroinflammation and CD8 T cell accumulation is frequently observed in postmortem brain tissue of patients with neurodegeneration. We therefore developed a murine model of brain atrophy using the Theiler's murine encephalomyelitis virus (TMEV) infection model of multiple sclerosis. We employ single major histocompatibility complex (MHC) class I molecule conditional knockout mice generated by our program to analyze the contribution of immune cell infiltration and onset of atrophy. TMEV infected C57BL/6 mice that singularly express H‐2K b or H‐2D b were evaluated. TMEV infection of these mice resulted in ventricular atrophy at 14 d.p.i. However, H‐2D b expressing mice presented with significantly greater and continuous ventricular atrophy compared to H‐2K b expressing mice and MHC class I knockout control mice. Flow cytometric analysis revealed H‐2D b expressing mice had greater brain infiltrating CD8 T cell responses at 7 and 28 dpi which correlated with the extent of ventricular atrophy. Meanwhile, H‐2K b and MHC class I knockout mice also had distinct positive correlations with ventricular atrophy and global neuroinflammation in general. These findings support the role of immune cell infiltration into the CNS as a putative mechanism of ventricular atrophy following TMEV infection, with the progressive enlargement of ventricular atrophy observed in H‐2D b mice being associated with the presence of long‐lived memory CD8 T cells residing in the brain.
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Janas, Anastasia , Baid, Ujjwal , Ramakrishnan, Divya , Saluja, Rachit , Ashraf, Nader, Maleki, Nazanin , Yordanov, Nikolay , Fehringer, Pascal, Gkampenis, Athanasios , Amiruddin, Raisa, Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammad, Bergquist, Timothy , Chiang, Veronica , Eddy, J. Mark , Ezhov, Ivan , Khalili, Nastaran, Jiang, Zhifan , Johanson, Elaine, Kazerooni, Anahita Fathi , Krantchev, Kiril, Linguraru, Marius George , Liu, Xinyang , Meier, Zeke, Moy, Harrison, Osenberg, Klara , Reitman, Zachary, Shinohara, Russell Takeshi, Wang, Chunhao , Shafique, Umber, Willms, Klara, Avesta, Arman , Bousabarah, Khaled , Chakrabarty, Satrajit , Gennaro, Nicolò , Holler, Wolfgang, Lost, Jan , Marcus, Daniel S. , Maresca, R, Merkaj, Sarah, Pedersen, Gabriel Cassinelli, Reppert, Marc von , Teytelboym, Oleg M., Tillmans, Niklas, Westerhoff, Malte , Youssef, Ayda , Pflüger, Irada, Perez-Carillo, Gloria J. Guzman, Memon, Fatima, Krycia, Mark, Patro, Satya Narayana , Petrović, Bojan , Schrickel, E. Brooke, Besada, Cristina , Chu, Sammy, Dusoi, Alexandru, Farage, Luciano , Fong, Amy, Gray, R. Ian, Krumpelman, Chase, Lincoln, Christie M. , Maros, Máté E. , Morón, Fanny , Nimchinsky, Esther A. , Patel, Uresh, Rohatgi, Saurabh , Sayah, Anousheh , Schwartz, Eric D. , Shiroishi, Mark S. , Valerie, Jewels, White, Matthew L. , Zohrabian, Vahe M. , Brüßeler, Melanie, Ghonim, Mohamed, Okar, Abdullah , Pasquini, L. , Soumala, Theodora, Taherzadeh, Mahsa , Vollmuth, Philipp, Foltyn, Martha , Abayazeed, Aly, Dellepiane, Francesco , Verdier, Maria Correia de , Al-Rubaiey, Sanaria, Ashraf, Kholod, Asla, Moamen M., Badawy, Mohamed , Lomer, Nima Broomand , Bukatz, Jan, Chen, Jim, Cimflová, Petra , Corr, Felix, Crawley, Alexis, Deptula, Lisa, Elakhdar, Tasneem, Shawali, Islam H., Frick, Alexandra, Haider, Muhammad Ammar , Hierro, Fátima , Jacobs, Sarah Maria, Hsieh, Kuang-chun Jim, Kersting, Katharina , Kida, Laura, Kollia, Sofia , Koukoulithras, Ioannis, Li, Xiao , Abouelatta, Ahmed, Mansour, Aya, Maria-Zamfirescu, Ruxandra-Catrinel, Marsiglia, Marcela , Mateo-Camacho, Yohana Sarahi , McArthur, Mark J., McDonnell, Olivia, McHugh, M, Moassefi, Mana , Morsi, Samah Mostafa, Munteanu, Alexander , Naqvi, Syed Raza, Nikanpour, Yalda , Alnoury, Mostafa , Nouh, Abdullah Mohamed Aly, Pappafava, Francesca, Patel, Markand D., Petrucci, S. , Rawie, Eric, Raymond, Scott B. , Roohani, Borna, Sabouhi, Sadeq, Sánchez‐García, Laura , Shaked, Zoe , Altes, Talissa A. , Isufi, Edvin , Dhemesh, Yaseen , Gass, Jaime, Thacker, Jonathan, Tarabishy, Abdul , Turner, Benjamin , Worede, Fikadu , Yousry, Sara, Lerebo, Wondwossen , Aristizábal, Alejandro , Karargyris, Alexandros , Kassem, Hasan , Sheller, Micah , Link, Katherine E. , Moawad, Ahmed W. , Ashraf, Nader, Jekel, Leon , Manteghinejad, Amirreza , Aneja, Sanjay , Anwar, Syed Muhammad, Chung, Verena , Conte, Gian Marco , Dako, Farouk , Eddy, James, Khalili, Nastaran, Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Piraud, Marie , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Kaur, Manpreet , LaMontagne, Pamela , Lin, MingDe , Maresca, Ryan, Petersen, Gabriel Cassinelli , Sotiras, Aristeidis , Godfrey, Devon , Floyd, Scott , Rauschecker, Andreas M. , Villanueva-Meyer, Javier E. , Cho, Jaeyoung , Bendszus, Martin , Brugnara, Gianluca , Cramer, Justin , Johnson, Derek R. , Kam, Anthony , Kwan, Benjamin Y. M. , Lai, Lillian M. , Lall, Neil , So, Tiffany Y. , Thompson, Gerard , Wu, Lei , Bansal, Anu , Barkhof, Frederik , Druzgal, T. Jason , Feltrin, Fabrício Stewan , Fung, Steve H. , Ikuta, Ichiro , Iv, Michael , Postma, Alida A. , Mahajan, Amit Kumar , Joyner, David , Létourneau‐Guillon, Laurent , Miller, Elka , Özsarlak, Ö. , Saha, Atin , Shih, Robert , Small, Juan E. , Tanwar, Manoj , Weinberg, Brent D. , Young, Robert J. , Azizova, Aynur , Ghonim, Mohanad , Ghonim, Mohamed, Sharifi, Yasaman , Singh, Gagandeep, Sollmann, Nico , Vollmuth, Philipp, Foltyn‐Dumitru, Martha , Malhotra, Ajay , Lohmann, Philipp , Pérez‐García, Víctor M. , Elhalawani, Hesham M. , Duarte Armindo, Rui , Asla, Moamen M., Bisschop, Jeroen , Faghani, Shahriar , Gulati, Vaibhav , Dahl, Rasmus Holmboe , McArthur, Mark, McHugh, Maire, Moassefi, Mana , Nandolia, Khanak , Petrucci, Samantha, Sanchez-Garcia, Laura M., Suthar, Pokhraj Prakashchandra , Vacca, Sebastiano , Vilanilam, George K. , Warren, Daniel, Weiss, David, Pati, Sarthak , Calabrese, Evan , Tahon, Nourel Hoda , Nada, Ayman , Velichko, Yury , Bakas, Spyridon , Rudie, Jeffrey D. , Aboian, Mariam

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: December 2025 | Pages: 204-247

10.59275/j.melba.2025-9bd3 Get It

The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. The mean scores for the teams were calculated. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. The Dice score for the winning team was 0.65 ± 0.25. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space. The Dice scores and lesion detection rates of all algorithms diminished with decreasing tumor size, particularly for tumors smaller than 100 mm3. In conclusion, algorithms for BM segmentation require further refinement to balance high sensitivity in lesion detection with the minimization of false positives and negatives. The BraTS-METS 2023 challenge successfully curated well- annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied environments and providing the tools for future development of personalized volumetric reports to patients undergoing BM treatment.
Tale of two approaches to ultrasound-guided interscalene brachial plexus block: a pro-con
Owen, Robert L. , VanderWielen, Beth A. , Johnson, Rebecca L. , Owen, Robert Loren , Johnson, Rebecca L , Amundson, Adam W.

Mayo Clinic

Regional Anesthesia & Pain Medicine | June 24, 2025 | Volume: 51 | Issue: 8 | Pages: 985-988

10.1136/rapm-2025-106624 | PMID 40555526 Get It

The interscalene brachial plexus block is a well-described and widely used peripheral nerve block effective for regional anesthesia and analgesia in orthopedic surgical procedures of the shoulder, upper arm, and clavicle. Conventionally, an in-plane ultrasound-guided approach has been the technique of choice, while the out-of-plane approach, though less described, has been gaining anecdotal momentum among a growing number of proceduralists. This pro-con discussion highlights the out-of-plane approach’s goal of avoiding needle injuries to nerves that course through the middle scalene muscle and the in-plane approach’s benefit of whole-shaft needle visualization and increased distance away from the plexus on entry. We aim to provide a comprehensive comparison to guide proceduralists in their clinical decision-making.